NASDAQ:REVB Revelation Biosciences Q2 2024 Earnings Report $1.03 -0.02 (-1.90%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$1.03 0.00 (-0.39%) As of 07:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Revelation Biosciences EPS ResultsActual EPS-$295.68Consensus EPS -$347.52Beat/MissBeat by +$51.84One Year Ago EPSN/ARevelation Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARevelation Biosciences Announcement DetailsQuarterQ2 2024Date8/9/2024TimeN/AConference Call DateFriday, August 9, 2024Conference Call Time7:00AM ETUpcoming EarningsRevelation Biosciences' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Revelation Biosciences Earnings HeadlinesREVB Poised for Big YearMay 8, 2026 | finance.yahoo.comRevelation Biosciences (REVB) price target decreased by 37.65% to 54.06March 28, 2026 | msn.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.June 25 at 1:00 AM | Weiss Ratings (Ad)Revelation Biosciences (REVB) price target increased by 300.00% to 86.70February 4, 2026 | msn.comREVB Comes to Agreement with FDAJanuary 29, 2026 | finance.yahoo.comREVB stock drops 10% after company announces third reverse split in a yearJanuary 26, 2026 | msn.comSee More Revelation Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Revelation Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Revelation Biosciences and other key companies, straight to your email. Email Address About Revelation BiosciencesRevelation Biosciences (NASDAQ:REVB), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.View Revelation Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why KB Home Could Reward Patient Investors LaterFedEx’s Earnings Drop May Be Missing the Bigger Freight StoryWhy nVent Could Be a Long-Term AI Infrastructure WinnerChevron’s Microsoft Deal Turns Natural Gas Into an AI TradeMicron’s Sudden Plunge May Be an AI Buying ChanceMarathon Petroleum Is Back, But Cycles Still MatterLiquid Gold: The AI Cooling Retrofit Trade Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
